251 related articles for article (PubMed ID: 15761016)
1. The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation.
Jungbluth AA; Ely S; DiLiberto M; Niesvizky R; Williamson B; Frosina D; Chen YT; Bhardwaj N; Chen-Kiang S; Old LJ; Cho HJ
Blood; 2005 Jul; 106(1):167-74. PubMed ID: 15761016
[TBL] [Abstract][Full Text] [Related]
2. Cellular immune responses against CT7 (MAGE-C1) and humoral responses against other cancer-testis antigens in multiple myeloma patients.
Lendvai N; Gnjatic S; Ritter E; Mangone M; Austin W; Reyner K; Jayabalan D; Niesvizky R; Jagannath S; Bhardwaj N; Chen-Kiang S; Old LJ; Cho HJ
Cancer Immun; 2010 Jan; 10():4. PubMed ID: 20108890
[TBL] [Abstract][Full Text] [Related]
3. MAGE-C1/CT7 and MAGE-C2/CT10 are frequently expressed in multiple myeloma and can be explored in combined immunotherapy for this malignancy.
de Carvalho F; Alves VL; Braga WM; Xavier CV; Colleoni GW
Cancer Immunol Immunother; 2013 Jan; 62(1):191-5. PubMed ID: 23180015
[TBL] [Abstract][Full Text] [Related]
4. Expression and prognostic relevance of MAGE-C1/CT7 and MAGE-C2/CT10 in osteolytic lesions of patients with multiple myeloma.
Pabst C; Zustin J; Jacobsen F; Luetkens T; Kröger N; Schilling G; Bokemeyer C; Sauter G; Atanackovic D; Marx A
Exp Mol Pathol; 2010 Oct; 89(2):175-81. PubMed ID: 20621094
[TBL] [Abstract][Full Text] [Related]
5. Targeting MAGE-C1/CT7 expression increases cell sensitivity to the proteasome inhibitor bortezomib in multiple myeloma cell lines.
de Carvalho F; Costa ET; Camargo AA; Gregorio JC; Masotti C; Andrade VC; Strauss BE; Caballero OL; Atanackovic D; Colleoni GW
PLoS One; 2011; 6(11):e27707. PubMed ID: 22110734
[TBL] [Abstract][Full Text] [Related]
6. Cancer-testis antigens MAGE-C1/CT7 and MAGE-A3 promote the survival of multiple myeloma cells.
Atanackovic D; Hildebrandt Y; Jadczak A; Cao Y; Luetkens T; Meyer S; Kobold S; Bartels K; Pabst C; Lajmi N; Gordic M; Stahl T; Zander AR; Bokemeyer C; Kröger N
Haematologica; 2010 May; 95(5):785-93. PubMed ID: 20015885
[TBL] [Abstract][Full Text] [Related]
7. Cancer/Testis Antigen MAGE-C1/CT7: new target for multiple myeloma therapy.
de Carvalho F; Vettore AL; Colleoni GW
Clin Dev Immunol; 2012; 2012():257695. PubMed ID: 22481966
[TBL] [Abstract][Full Text] [Related]
8. Longitudinal analysis and prognostic effect of cancer-testis antigen expression in multiple myeloma.
Atanackovic D; Luetkens T; Hildebrandt Y; Arfsten J; Bartels K; Horn C; Stahl T; Cao Y; Zander AR; Bokemeyer C; Kröger N
Clin Cancer Res; 2009 Feb; 15(4):1343-52. PubMed ID: 19190130
[TBL] [Abstract][Full Text] [Related]
9. Expression of MAGE-C1/CT7 and MAGE-C2/CT10 predicts lymph node metastasis in melanoma patients.
Curioni-Fontecedro A; Nuber N; Mihic-Probst D; Seifert B; Soldini D; Dummer R; Knuth A; van den Broek M; Moch H
PLoS One; 2011; 6(6):e21418. PubMed ID: 21738656
[TBL] [Abstract][Full Text] [Related]
10. Expression of cancer/testis (CT) antigens MAGE-A1, MAGE-A3, MAGE-A4, CT-7, and NY-ESO-1 in malignant gammopathies is heterogeneous and correlates with site, stage and risk status of disease.
Dhodapkar MV; Osman K; Teruya-Feldstein J; Filippa D; Hedvat CV; Iversen K; Kolb D; Geller MD; Hassoun H; Kewalramani T; Comenzo RL; Coplan K; Chen YT; Jungbluth AA
Cancer Immun; 2003 Jul; 3():9. PubMed ID: 12875607
[TBL] [Abstract][Full Text] [Related]
11. Expression of MAGE-C1/CT7 and selected cancer/testis antigens in ovarian borderline tumours and primary and recurrent ovarian carcinomas.
Zimmermann AK; Imig J; Klar A; Renner C; Korol D; Fink D; Stadlmann S; Singer G; Knuth A; Moch H; Caduff R
Virchows Arch; 2013 May; 462(5):565-74. PubMed ID: 23529156
[TBL] [Abstract][Full Text] [Related]
12. Fine analysis of spontaneous MAGE-C1/CT7-specific immunity in melanoma patients.
Nuber N; Curioni-Fontecedro A; Matter C; Soldini D; Tiercy JM; von Boehmer L; Moch H; Dummer R; Knuth A; van den Broek M
Proc Natl Acad Sci U S A; 2010 Aug; 107(34):15187-92. PubMed ID: 20696919
[TBL] [Abstract][Full Text] [Related]
13. The clinical value of the quantitative detection of four cancer-testis antigen genes in multiple myeloma.
Zhang Y; Bao L; Lu J; Liu KY; Li JL; Qin YZ; Chen H; Li LD; Kong Y; Shi HX; Lai YY; Liu YR; Jiang B; Chen SS; Huang XJ; Ruan GR
Mol Cancer; 2014 Feb; 13():25. PubMed ID: 24499297
[TBL] [Abstract][Full Text] [Related]
14. CT10: a new cancer-testis (CT) antigen homologous to CT7 and the MAGE family, identified by representational-difference analysis.
Güre AO; Stockert E; Arden KC; Boyer AD; Viars CS; Scanlan MJ; Old LJ; Chen YT
Int J Cancer; 2000 Mar; 85(5):726-32. PubMed ID: 10699956
[TBL] [Abstract][Full Text] [Related]
15. Cancer-testis antigen 7 expression and immune responses following allogeneic stem cell transplantation for multiple myeloma.
Tyler EM; Jungbluth AA; Gnjatic S; O'Reilly RJ; Koehne G
Cancer Immunol Res; 2014 Jun; 2(6):547-58. PubMed ID: 24894092
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic modulation of MAGE-A3 antigen expression in multiple myeloma following treatment with the demethylation agent 5-azacitidine and the histone deacetlyase inhibitor MGCD0103.
Moreno-Bost A; Szmania S; Stone K; Garg T; Hoerring A; Szymonifka J; Shaughnessy J; Barlogie B; Prentice HG; van Rhee F
Cytotherapy; 2011 May; 13(5):618-28. PubMed ID: 21171821
[TBL] [Abstract][Full Text] [Related]
17. Is there any relationship between gene expression of tumor antigens and CD4+ T cells in multiple myeloma?
Braga WM; da Silva BR; Alves VL; Bortoluzo AB; Atanackovic D; Colleoni GW
Immunotherapy; 2014; 6(5):569-75. PubMed ID: 24896625
[TBL] [Abstract][Full Text] [Related]
18. Identification of MAGE-C1 (CT-7) epitopes for T-cell therapy of multiple myeloma.
Anderson LD; Cook DR; Yamamoto TN; Berger C; Maloney DG; Riddell SR
Cancer Immunol Immunother; 2011 Jul; 60(7):985-97. PubMed ID: 21461886
[TBL] [Abstract][Full Text] [Related]
19. Prognostic impact of cancer/testis antigen expression in advanced stage multiple myeloma patients.
Andrade VC; Vettore AL; Felix RS; Almeida MS; Carvalho F; Oliveira JS; Chauffaille ML; Andriolo A; Caballero OL; Zago MA; Colleoni GW
Cancer Immun; 2008 Feb; 8():2. PubMed ID: 18237105
[TBL] [Abstract][Full Text] [Related]
20. MAGE-C1/CT-7 expression in plasma cell myeloma: sub-cellular localization impacts on clinical outcome.
Tinguely M; Jenni B; Knights A; Lopes B; Korol D; Rousson V; Curioni Fontecedro A; Cogliatti SB; Bittermann AG; Schmid U; Dommann-Scherrer C; Maurer R; Renner C; Probst-Hensch NM; Moch H; Knuth A; Zippelius A
Cancer Sci; 2008 Apr; 99(4):720-5. PubMed ID: 18307538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
